We are reporting the case of severe methemoglobinemia resulting from Almagel which was given for treatment of gastrointestinal ulcers after pancreatoduodenal resection. A 64 year old man was treated with Almagel A postoperatively. One day after treatment began, the patient reported what appeared to be cyanotic discolorations of his lips and fingers. (SpO 2 80%, normal pO 2 ). Two days later, the patient was diagnosed with methemoglobinemia via co-oximetry and treated with methylene blue. The causes of methemoglobinemia remained unclear, and Almagel A was reinitiated until the second episode of methemoglobinemia, was diagnosed and treated promptly. The dose of benzocaine in Almagel A (100 mg/5 ml) was sufficient enough to cause methemoglobinemia, confirmed using multiwavelength co-oximeter and successfully treated with methylene blue.
Introduction
Methemoglobin is an altered state of hemoglobin whereby the ferrous form of iron (Fe 2+ ) is oxidized to the ferric state (Fe 3+ ), making the heme moiety incapable of carrying oxygen [1] . Normally accounting for about 1% of all circulating hemoglobin, methemoglobin is then reduced back to hemoglobin, mainly by the activity of the cytochrome-b5-methemoglobinemia (MHb) reductase system [2] .
Besides congenital forms, methemoglobinemia develops in the presence of oxidizing agents, such as benzocaine-containing topical anaesthetic sprays, and it is characterized by cyanosis. If untreated, methemoglobinemia may prove lethal [3] .
Here we report a case of severe acquired methemoglobinemia complicating treatment with Almagel after pancreatoduodenal resection. Almagel is an antacid medication in combination with a local anaesthestic (benzocaine) preferentially used in Eastern Europe for the prophylaxis and treatment of peptic ulcers and meteorism. The standard single dose 5 ml of Almagel suspension contains Aluminium hydroxide gel 300 mg, Magnesium hydroxide gel 100 mg, Benzocaine 100 mg and Sorbitol 800 mg (Actavis Nordic A/S, Denmark) [4] . The single dose for an adult can be increased to 2 and even 3 measuring spoonfuls in the presence of pain given 1-2 hours after meal and at bedtime. Due to the risk of methemoglobinemia the duration of treatment should not exceed 3 days. After the pain has passed treatment should be continued with Almagel which does not contain benzocaine.
By bringing the attention of other clinicians to the knowledge of potential side-effects of all prescribed medication and their constituting parts, we presume that this report will result in improved recognition and prompt treatment.
Case Description
The approval was obtained from the Ethics Committee, Lithuanian University of Health Sciences to review the patient case history, and the patient signed a written informed consent.
A 64 year old male patient was admitted to the Department of Surgery for elective pancreatoduodenal resection due to papilla Vateri carcinosis and operation was initiated. There were postoperative complications, due to the formation of an intraperitoneal abscess which was treated via drainage and antibiotics. On the eighth day after the surgery, haemorrhage from erosions in the oesophagus, ventricular and jejunal ulcers distally from anastomosis were diagnosed. A feeding tube was inserted for enteral nutrition, and treatment with omeprazole and Almagel A 30 ml (5 ml measuring spoonfuls 6 times) daily were started.
The following day, the patient presented with complaints of cyanotic discolorations of the lips and fingers; the patient denied any dyspnea His arterial blood pressure was 130/60 mmHg, heart rate 130 beats per minute, and SpO 2 was 80%. Arterial blood gases analysis showed normal values ( Table 1 ). The consulting internist suspected pulmonary thromboembolism and ordered a chest X-ray, D-dimer and troponin I tests. Chest X-ray revealed a disc atelectasis in the inferior right lung with no pathological findings in the lung or pleural cavity. Oxygen via a nasal catheter was added and the dose of fraxiparine was increased to 0.6 ml twice per day.
The treatment gave no improvement, the patient was transferred to the intensive care unit the following day. The patient was conscious, cyanotic but without dyspnea, rate of breathing 16 per min, SpO 2 70%, BP 148/84 mmHg, and HR 103 bpm. The results of blood cell count, biochemistry, coagulation tests and ECG were normal. The blood sample for assessment of blood gases was repeated (Table 1) . Blood sampling revealed an unusual dark colour of blood, and an extra sample was taken in 30 minutes. A special analysis with multiwavelength co-oximeter demonstrated methemoglobinemia (Met Hb 51%) which resolved in 4 hours after treatment with methylene blue. The patient was given nasal oxygen, both nutritional mixture and drinking water were changed and Almagel discontinued. Despite the consultation of a toxicologist the cause of methemoglobinemia remained unclear. The patient's state improved in several hours with the rise of SpO 2 from 70 to 79-90%. The patient himself had no complaints, the same as it was before, and was transferred to the department of surgery. Treatment with Almagel was restarted.
Another episode of cyanosis of the face and lips returned five days later, with SpO 2 78% and he was transferred to the intensive care unit. The patient's condition mimicked that of his previous admission to the ICU. His vitals were as follows: conscious, no dyspnea, the rate of breathing 16-18 per min, SpO 2 91-92%, BP 156/87 mmHg, and HR 63 bpm. Arterial gases sampling revealed the level of MetHb 32.5% which reduced to 4% subsequently in 2 hours after the treatment with methylene blue (Table 1) . After 2 hours the patient was transferred to the department of surgery. The following postoperative course was uneventful and in 1 week the patient was discharged from the hospital.
Discussion
The case represents a rare complication of methemoglobinemia after treatment with Almagel. After ruling out other potential external oxidants, this medication containing local anaesthetic benzocaine was the only possible cause of acquired methemoglobinemia. Methemoglobin is hemoglobin with ferric heme (Fe 3+ ) instead of ferrous (Fe 2+ ) heme, unable to form a bond with oxygen and transport it. Because red blood cells are continuously exposed to various oxidant stresses, blood normally contains approximately 1% methemoglobin levels [2] . The concentration of methemoglobin is kept low by the effect of cytochrome b5 methemoglobin reductase, which is dependent on reduced nicotine adenine dinucleotide (NADH) [5] . Methemoglobinemia is defined as an abnormal elevation of methemoglobin levels and has 3 different etiologic categories: (1) an autosomal dominant trait that causes production of abnormal hemoglobin; (2) an autosomal recessive trait resulting in decreased activity of methemoglobin reductase, typically resulting in subclinical MHb; and (3) introduction of an external oxidising agent, which overwhelms the reducing capacity of red blood cells (the most common cause of MHb) [2] .There are two basic mechanisms of acquired methemoglobinemia: direct or indirect oxidation of the hemoglobin. Direct oxidation can be caused by chlorates, hexavalent chromates, cobalt, and copper salts [6] . More prevalent indirect oxidation occurs with participation of both the iron and the oxygen, with hydrogen peroxide and superoxide production [7] . Acquired methemoglobinemia develops after oxygenation of hemoglobin by pharmacological substances or toxins (aniline dye, anaesthetics -benzocaine, prilocaine; naphthalene, nitrates, nitrites, etc.) [1, 8] . Reactions involved for local anaesthetic-induced methemoglobinemia are: hydrolysis of the amide to the corresponding amine, metabolism of the amine to the appropriate species, and direct oxidation of hemoglobin by the amine metabolite. The nature of the amine liberated on hydrolysis is the major determining factor in the methemoglobin-forming ability of amides [5, 9] .
There are several groups of patients particularly susceptible to oxidative stress. Children younger than 4 months may have underdeveloped protective mechanisms (NADH methemoglobin reductase). Potential risk factors include greater concentration in topical anaesthetic gel or ointment, increased systemic absorption from mucosal surfaces, compromised or abraded skin, mucosal erosions, inflamed airways, gastrointestinal infections, and the addition of occlusive dressing [1, 10] .
The incidence of methemoglobinemia related to benzocaine has been reported as high as 1 in 7,000 exposures [11] , 0.115% for the first exposure and 0.345% if there are 2 exposures within 1 week [12] . Among 198 reported adverse events of all types associated with benzocaine, in 93.2% of cases the product was a spray, in 1.5%, a benzocaine-containing lozenge, and in 1 case it was gel [2] . Some patients have developed the syndrome with a single 1 s or short spray of 20% solution on mucous membrane: exact dose impossible to determine, anywhere from <76 mg to 212 mg [13] . Factors predisposing methemoglobinemia after benzocaine use are not known, and the lack of correlation between the dose and adverse effect is very concerning [14] . Up to 35% of topical benzocaine, when applied to mucous membranes, can be absorbed systemically [11, 15] . Systemic cyanosis and methemoglobinemia for an adult can be caused by 150-300 mg of benzocaine [16] . Because it is impossible to predict which individual will be susceptible to develop methemoglobinemia after benzocaine exposure, and also because there is no therapeutic window in susceptible individuals, some authors have even recommended abandoning the clinical use of benzocaine [5] . It would be valuable to have plasma concentration of benzocaine determined as well as measured at any time you suspect a toxic event. However, it remains a theoretical option because there are no either technical possibilities to perform it in our institution or publications reporting having it measured. Diagnosis of methemoglobinemia is based on: cyanosis of skin and mucosa resistant to treatment with oxygen when there are no other causes (cardiovascular and pulmonary diseases), chocolate brown colour of blood, elevated level of blood metHb, fact of possible poisoning. One can suspect methemoglobinemia when cyanosis of the skin doesn't correlate with dyspnea, while blood gas or pulse oximetry readings can be near normal [2] . Oxygen saturation is non-specific, varying between 50% and 94%, median 85%; a discrepancy between the pulse oximeter saturation (≤90%) and the measured arterial oxygen partial pressure (PaO 2 ≥70 mm Hg) suggests methemoglobinemia [5] . The diagnosis relies mainly on the co-oximeter measurement of an elevated circulating level of methemoglobin (>1% or 2%) [5] .
According to the classical description, clinical signs in addition to cyanosis appear only when the level of metHb reaches 25-50%, and they are as follows: headache, dyspnea, dizziness, weakness, disorientation, palpitations, and chest pain. When the level of metHb reaches 50-70%, cardiovascular (arrhythmias), CNS (disturbed consciousness, delirium, seizures, and coma) and metabolic complications occur [2] . In contrast, symptoms may occur below the critical 30% level often quoted as the cut-off point for methylene blue administration [5] . Ash-Bernal et al. [17] stated that most patients were symptomatic with ≥8% of methemoglobin. Untreated methemoglobinemia can result in adverse outcomes or even death. Among the analyzed 242 cases three patients had non-Q wave myocardial infarction (methemoglobin 17%-67.8%), one case resulted in severe neurological impairment, and one 52-year-old man with previous dyspnea after pharyngeal benzocaine spray developed respiratory, renal, liver failure and died after cardiac arrest despite treatment with methylene blue [5] . This combination of symptoms reflects the intolerance of the brain and heart to anaerobic metabolism, a direct consequence of the tissue hypoxia caused by methemoglobinemia [14] .
In our case it took 2 days from the symptoms of cyanosis to the diagnosis of methemoglobinemia when the level of metHb had reached a dangerous margin of 51%. Conventional pulse oximetry in combination with blood gases did not reveal the cause of cyanosis. Ordinary two wavelength pulse oximeters are not able to measure total hemoglobin and dyshemoglobins (carboxy-, methemoglobin) [18] . Modern multiwavelength pulse oximeters capable of measuring carboxyhemoglobin, methemoglobin and total hemoglobin noninvasively with accuracy comparable to co-oximeters have recently been introduced into the market by Masimo Corp. [18] . It would have been helpful in our situation if it were available. However, laboratory test -direct measure of metHb with multiwavelength co-oximeter confirmed the diagnosis.
Specific treatment for methemoglobinemia -methylene blue-was effective in our case. In a dose of 1 to 2 mg/kg body weight it is the preferred treatment. Methylene blue acts as a reducing agent via the NADPH methemoglobin reductase pathway. It converts ferric iron back to the ferrous state and restores the oxygen-carrying capacity of hemoglobin [19] .
Despite effective treatment, the underlying cause of methemoglobinemia remained unclear. At first, external causes but not medication were carefully assessed and ruled out (drinking water, enteral nutrition). Despite this, there was a repeated episode of methemoglobinemia.
It was diagnosed promptly with the level of methemoglobin of 31% and treated successfully. Finally, Almagel containing benzocaine was found to be the only cause of methemoglobinemia, and it was stopped. Almagel A, a preparation with an antacid and local anaesthetic effect, was used for treatment of postoperative gastrointestinal ulcers. Usage longer than 3 days is not recommended due to the presence of benzocaine in the medication [4] .
Until now, there has been a single publication on Almagel-induced methemoglobinemia in newborn infants dating back to 1989 in a Russian journal. In that case, a different kind of Almagel containing D-sorbitol nitrate was used. The authors stated that the toxic nitrate compound which is slowly absorbed to the blood but if absorbed, then tightly connected to blood globins was the cause of severe methemoglobinemia [20] .
In conclusion, severe methemoglobinemia in our particular case was induced by Almagel containing local anaesthetic benzocaine. The dose of benzocaine in the suspension of Almagel A (100 mg/5 ml) was sufficient to cause methemoglobinemia. Faster systemic resorption of benzocaine may have been speeded up by oesophageal erosions and big ventricular ulcers. In the repeated episode, the risk of methemoglobinemia may have been increased by prolonged uptake of Almagel A (5 days). Methemoglobinemia was difficult to diagnose during the first episode without multiwavelength co-oximeter, and the cause remained unclear until the second episode. Both episodes were successfully treated with specific antidote methylene blue. When treating patients with medication containing multiple compounds one must remember the potential and sometimes hazardous side effects of each of the constituting parts.
